Join Steven M. Horwitz, MD, Member and Attending Physician at Memorial Sloan Kettering Cancer Center, as he discusses guideline recommendations for differential diagnosis of TCL, novel treatment strategies, and best practices for managing side effects in this case-based live webinar! Register today!
Learn more about emerging evidence on immunotherapeutic strategies for advanced MCC and multidisciplinary approaches to monitor and manage immune-related adverse events in patients with advanced MCC in this activity presented by Shailender Bhatia, MD, and Ciara Kelly, MBBCh, BAO. Start now to earn CME/NCPD!
In this activity, Oliver Sartor, MD, discusses patient and tumor characteristics that can inform tailored therapeutic approaches for patients with metastatic HSPC, evaluates emerging data on novel treatment combinations and sequences for patients with metastatic HSPC, and assesses strategies to optimize the safety and tolerability of novel therapies for metastatic HSPC. Start now to earn free CME/NCPD!
In this NCPD activity, Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, identifies prognostic markers that impact treatment selection and treatment goals to individual patients with metastatic breast cancer (MBC), evaluates the efficacy and safety profiles of novel therapies for HER2-positive, HER2-negative, and triple-negative MBC, and more. Complete the activity now to earn free NCPD!
This free online CME/NCPD activity on first-line and second-line treatment for advanced renal cell carcinoma is presented by Bradley McGregor, MD, and Robert Motzer, MD. It is also available as a podcast. Start the activity now!
This NCPD activity, presented by Laura S. Wood, RN, MSN, OCN, discusses mechanisms of action of IO agents and VEGFR TKIs, efficacy and safety profiles of IO and VEGFR TKI therapies, and strategies to improve treatment tolerability for advanced renal cell carcinoma. Start now!
In this virtual tumor board, Sara M. Tolaney, MD, MPH, Ira J. Bleiweiss, MD, and Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, assess predictive and prognostic markers for MBC, evaluate current and emerging data on therapeutic approaches for HER2-positive, hormone receptor-positive/HER2-negative, and triple-negative MBC, and apply strategies to manage adverse events for MBC. Start now!
This CME virtual tumor board, presented by Loretta J. Nastoupil, MD, Reem Karmali, MD, MS, and Francisco Vega, MD, PhD, evaluates emerging efficacy and safety data on novel therapeutic approaches, discusses the implications of POD24 status in therapeutic decision making for patients, and applies strategies to optimize treatment experiences and outcomes for patients with relapsed/refractory FL. Start now!
In this virtual tumor board, Vicki L. Keedy, MD, MSCI, Brian P. Rubin, MD, PhD, and Kathleen Polson, NP, discuss diagnostic evaluation, treatment selection, and supportive care strategies for patients with soft tissue sarcoma.
This NCPD activity, presented by Allison Miller Imahiyerobo, APN, includes cases that provide insight into nursing management of ITP. In addition, Ms. Miller Imahiyerobo discusses the pathogenesis of ITP and differentiates the efficacy and safety profiles of current and emerging ITP therapies.
In this NCPD activity, Amy L. Goodrich, RN, MSN, CRNP-AC, evaluates guideline recommendations for the management of patients with advanced NHL, assesses emerging efficacy and safety data on novel therapies for advanced NHL, and applies strategies to manage adverse events and optimize treatment experiences for patients receiving novel therapies for NHL. Start now!